Playback speed
10 seconds
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- mBC
By
ecancer
FEATURING
Virginia Kaklamani
By
ecancer
FEATURING
Virginia Kaklamani
2,418 views
January 10, 2023
This video was recorded prior to FDA approval of ORSERDU™ (elacestrant) on January 27, 2023 ...
read more ↘ in ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed on at least 1 line of endocrine therapy
↖ read less
read more ↘ in ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed on at least 1 line of endocrine therapy
↖ read less
Login to view comments.
Click here to Login